Hoechst Japan Buys R-PR Japan's Generics

5 December 1994

German chemical and pharmaceutical group Hoechst has said that its Japanese arm is to acquire the generics business of Rhone-Poulenc Rorer Japan.

Hoechst Japan established a wholly-owned subsidiary at the end of October, Cox Japan. It will merge the business, the Berk division, it is acquiring from R-PR with this unit. Terms of the deal were not disclosed. Cox' headquarters is in Tokyo and production and development is in Yamagata Ken. Cox will be run as a separate subsidiary of Hoechst Japan, but the latter said that it will be closely coordinated with the traditional pharmaceutical business.

"In the first phase, we will continue the present business but try to strengthen it by bringing in new products from the other generics companies of the Hoechst-Roussel group and also from third parties, and by improving marketing and distribution," said Thomas Hofstaetter, executive managing director of Hoechst Japan's pharmaceutical unit, at a local press conference last week.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight